anti-Apolipoprotein B MRNA Editing Enzyme, Catalytic Polypeptide-Like 3B (APOBEC3B) Anticorps

APOBEC3B is a member of the cytidine deaminase gene family. De plus, nous expédions APOBEC3B Protéines (5) et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
APOBEC3B 9582 Q9UH17
APOBEC3B 315137  
APOBEC3B    
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top anti-APOBEC3B Anticorps sur anticorps-enligne.fr

Showing 10 out of 44 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Fournisseur Livraison Prix Détails
Boeuf (Vache) Lapin Inconjugué WB WB Suggested Anti-APOBEC3B Antibody Titration:  0.2-1 ug/ml  Positive Control:  HepG2 cell lysate Host:  Rabbit  Target Name:  APOBEC3B  Sample Type:  HepG2  Lane A:  Primary Antibody  Lane B:  Primary Antibody + Blocking Peptide  Primary Antibody Concentration:  1ug/ml  Peptide Concentration:  5ug/ml  Lysate Quantity:  25ug/lane/lane  Gel Concentration:  0.12 100 μL Connectez-vous pour afficher 2 to 3 Days
$319.00
Détails
Humain Lapin Inconjugué WB 50 μg Connectez-vous pour afficher 11 to 14 Days
$551.83
Détails
Humain Lapin Inconjugué IHC, IP, WB Western blot analysis of extracts of various cell lines, using APOBEC3B antibody. 100 μL Connectez-vous pour afficher 16 Days
$366.77
Détails
Humain Lapin Inconjugué WB Western Blot: APOBEC3B Antibody [NBP1-57516] - HepG2 cell lysate, concentration 0.2-1 ug/ml. Western Blot: APOBEC3B Antibody [NBP1-57516] - Sample Tissue: HepG2, Lane A: Primary Antibody, Lane B: Primary Antibody + Blocking Peptide, Primary Antibody Concentration: 1ug/ml, Peptide Concentration: 5ug/ml, Lysate Quantity: 25ug/lane/lane, Gel Concentration: 0.12 100 μL Connectez-vous pour afficher 8 to 11 Days
$559.35
Détails
Humain Lapin Inconjugué ELISA, WB 50 μg Connectez-vous pour afficher 2 to 3 Days
$446.88
Détails
Humain Lapin Inconjugué ELISA, IF, IHC (p), WB   0.1 mg Connectez-vous pour afficher 2 to 3 Days
$360.00
Détails
Humain Lapin Inconjugué WB Western blot analysis of extracts of various cell lines, using APOBEC3B antibody. 200 μL Connectez-vous pour afficher 12 to 14 Days
$438.90
Détails
Humain Lapin Inconjugué ELISA, WB   100 μg Connectez-vous pour afficher 15 to 19 Days
$527.03
Détails
Humain Lapin Inconjugué ELISA, IF, IHC, IHC (p), WB   50 μg Connectez-vous pour afficher 11 to 14 Days
$484.00
Détails
Humain Lapin Inconjugué IP, WB   200 μL Connectez-vous pour afficher 13 to 14 Days
$487.50
Détails

Plus d’anticorps contre APOBEC3B partenaires d’interaction

Human Apolipoprotein B MRNA Editing Enzyme, Catalytic Polypeptide-Like 3B (APOBEC3B) interaction partners

  1. APOBEC3B upregulation and APOBEC mutation count can be used as novel predictive markers in guiding NSCLC checkpoint blockade immunotherapy.

  2. We identified genes harboring CNVs that are highly differentiated between PM and global populations, indicating that these genes are predominantly enriched in immune responses and defense functions, including APOBEC3A_B, beta-defensin genes, and CCL3L1, followed by other biological functions, such as drug and toxin metabolism and responses to radiation

  3. the knockdown of APOBEC3B by clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 resulted in reduced proliferation and enhanced chemosensitivity of glioma cells. Thus, APOBEC3B contributes to glioma progression and may be a future target for therapeutic intervention.

  4. results suggest that B-Myb-A3B contributes to DNA damage and could be targeted by inhibiting EGF receptor.

  5. APOBEC3A/B deletion was associated with young age at diagnosis among the cancer cases for both cancer forms (lung cancer: P = 0.02; dominant model and prostate cancer

  6. These studies combine to indicate that APOBEC3B promotes drug resistance in breast cancer and that inhibiting APOBEC3B-dependent tumor evolvability may be an effective strategy to improve efficacies of targeted cancer therapies.

  7. Our results provide evidence that APOBEC3B can interact with HBV core protein and edit HBV DNAs during reverse transcription. These data suggest that APOBEC3B exerts multifaceted antiviral effects against HBV.

  8. review of current understanding of APOBEC3A and APOBEC3B biology in human papillomavirus Infection restriction, evolution, and associated cancer mutagenesis

  9. This study found that A3B C-terminal domain shows higher activity toward its target sequence in short ssDNA and efficiently deaminates a target sequence located near the center of ssDNA.

  10. Data show that the larger oligomeric state of APOBEC3B (A3B) inhibited its activity.

  11. APOBEC3B*c.783delG showed evidence of modest association with breast cancer and seemed to contribute to earlier onset of the disease.

  12. Data show that APOBEC3B (A3B) expression is inversely related to p53 status in different cancer types and demonstrate that this is due to a direct and pivotal role for p53 in repressing A3B expression.

  13. Structural determinants of APOBEC3B non-catalytic domain for molecular assembly and catalytic regulation have been reported.

  14. A lysine-free derivative of human APOBEC3B was constructed and shown to be indistinguishable from the wild-type enzyme in DNA cytosine deamination, HIV-1 restriction, and nuclear localization activities.

  15. exposures to relevant environmental factors might induce APOBEC3A or APOBEC3B expression above genotoxic levels and initiate tumorigenesis in a tissue-specific manner in the right cellular environment where ssDNA is available

  16. APOBEC3B expression increased the incorporation of genomic uracil, invoked DNA damage response (DDR) biomarkers and caused cell cycle arrest.

  17. The findings demonstrate that covalently-closed circular DNA levels are significantly lower in hepatocellular carcinoma tissues, and that the lower levels are likely to stem in part from up-regulation of APOBEC3B.

  18. Data suggest that heat shock proteins, in particular Hsp90, stimulate APOBEC3-mediated DNA deamination activity toward hepatitis B viral DNA, suggesting a potential physiological role in mutagenesis/carcinogenesis and viral innate immunity; Hsp90 stimulates deamination activity of APOBEC3G, APOBEC3B, and APOBEC3C during co-expression in human liver HepG2 cells.

  19. APOBEC3B mRNA levels are significantly higher in breast cancer metastases as compared to the corresponding estrogen receptor-positive primary tumors.

  20. tumour-infiltrating immune cells may be an important feature of breast cancers arising in women with APOBEC3B germline deletion, and that this may be of particular interest in Asian women where the germline deletion is more common.

Pig (Porcine) Apolipoprotein B MRNA Editing Enzyme, Catalytic Polypeptide-Like 3B (APOBEC3B) interaction partners

  1. Porcine endogenous retrovirus type C infectivity was strongly inhibited by poA3Z2-Z3, but it did not markedly reduce porcine endogenous retrovirus type B infectivity.

  2. These results strongly imply that human and porcine APOBEC3 could inhibit porcine endogenous retroviruses replication in vivo, thereby reducing the risk of infection of human cells in the context of pig-to-human xenotransplantation.

APOBEC3B profil antigène

Profil protéine

This gene is a member of the cytidine deaminase gene family. It is one of seven related genes or pseudogenes found in a cluster, thought to result from gene duplication, on chromosome 22. Members of the cluster encode proteins that are structurally and functionally related to the C to U RNA-editing cytidine deaminase APOBEC1. It is thought that the proteins may be RNA editing enzymes and have roles in growth or cell cycle control. A hybrid gene results from the deletion of approximately 29.5 kb of sequence between this gene, APOBEC3B, and the adjacent gene APOBEC3A. The breakpoints of the deletion are within the two genes, so the deletion allele is predicted to have the promoter and coding region of APOBEC3A, but the 3' UTR of APOBEC3B. Two transcript variants encoding different isoforms have been found for this gene.

Gene names and symbols associated with APOBEC3B

  • apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) anticorps
  • apolipoprotein B mRNA editing enzyme catalytic subunit 3B (Apobec3b) anticorps
  • A3B anticorps
  • APOBEC1L anticorps
  • Apobec3 anticorps
  • APOBEC3B anticorps
  • APOBEC3F anticorps
  • APOBEC3Z2 anticorps
  • APOBEC3Z3 anticorps
  • ARCD3 anticorps
  • ARP4 anticorps
  • bK150C2.2 anticorps
  • DJ742C19.2 anticorps
  • PHRBNL anticorps

Protein level used designations for APOBEC3B

DNA dC->dU-editing enzyme APOBEC-3B , cytidine deaminase , phorbolin 2 , phorbolin 3 , phorbolin-1-related protein , phorbolin-2/3 , probable DNA dC->dU-editing enzyme APOBEC-3B , apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B , apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D , DNA dC->dU-editing enzyme APOBEC3 , apolipoprotein B editing complex 3 , apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F , probable DNA dC->dU-editing enzyme APOBEC3 , apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B

GENE ID SPECIES
9582 Homo sapiens
743891 Pan troglodytes
315137 Rattus norvegicus
100037939 Sus scrofa
100628312 Macaca mulatta
Fournisseurs de qualité sélectionnés pour anti-APOBEC3B (APOBEC3B) Anticorps
Avez-vous cherché autre chose?